The C/EBPβ antagonist peptide lucicebtide (ST101) induces macrophage polarization toward a pro-inflammatory phenotype and enhances anti-tumor immune responses

The C/EBPβ antagonist peptide lucicebtide (ST101) induces macrophage polarization toward a pro-inflammatory phenotype and enhances anti-tumor immune responses

Immune-checkpoint inhibitors (ICIs) have shown unprecedented success in a subset of immunogenic tumors, however a host of patients with advanced solid tumors fail to respond well or at all to immunotherapy. Refractory tumors commonly display a tumor microenvironment (TME) rich in immunosuppressive m...

Full description

Bibliographic Details
Main Authors: Claudio Scuoppo, Rick Ramirez, Siok F. Leong, Mark Koester, Zachary F. Mattes, Karen Mendelson, Julia Diehl, Franco Abbate, Erin Gallagher, Lila Ghamsari, Abi Vainstein-Haras, Gene Merutka, Barry J. Kappel, Jim A. Rotolo
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Immunology
Subjects:
C/EBPβ
lucicebtide
tumor associate macrophages (TAM)
M2-type macrophage
anti-pd 1 immunotherapy
ST101
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1522699/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1522699/full

Similar Items